UBS Group assumed coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report report published on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 price objective on the stock.

TXG has been the subject of several other research reports. Morgan Stanley decreased their price target on shares of 10x Genomics from $70.00 to $64.00 and set an overweight rating for the company in a report on Friday, November 4th. JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $65.00 to $55.00 in a research note on Thursday, November 3rd. The Goldman Sachs Group reduced their price objective on shares of 10x Genomics from $35.00 to $25.00 and set a sell rating for the company in a research note on Thursday, October 13th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of 10x Genomics in a report on Tuesday, December 13th. They issued a buy rating and a $50.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, 10x Genomics has a consensus rating of Hold and a consensus price target of $50.90.

10x Genomics Trading Down 3.6 %

Shares of NASDAQ TXG traded down $1.79 during trading on Thursday, reaching $47.93. The company had a trading volume of 111,934 shares, compared to its average volume of 1,146,258. The business's 50 day moving average price is $39.36 and its 200-day moving average price is $35.90. 10x Genomics has a 52 week low of $23.81 and a 52 week high of $99.14.

Insider Buying and Selling

In other 10x Genomics news, insider Benjamin J. Hindson sold 2,361 shares of the business's stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total value of $80,439.27. Following the transaction, the insider now directly owns 217,713 shares in the company, valued at $7,417,481.91. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other 10x Genomics news, CEO Serge Saxonov sold 2,676 shares of the business's stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total value of $91,171.32. Following the completion of the transaction, the chief executive officer now owns 974,926 shares of the company's stock, valued at approximately $33,215,728.82. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Benjamin J. Hindson sold 2,361 shares of the company's stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total transaction of $80,439.27. Following the completion of the sale, the insider now directly owns 217,713 shares of the company's stock, valued at approximately $7,417,481.91. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,663 shares of company stock worth $227,008. 11.08% of the stock is owned by insiders.

Institutional Investors Weigh In On 10x Genomics

A number of institutional investors have recently made changes to their positions in TXG. SRS Investment Management LLC boosted its stake in shares of 10x Genomics by 1,214.3% in the 2nd quarter. SRS Investment Management LLC now owns 2,758,245 shares of the company's stock valued at $124,811,000 after purchasing an additional 2,548,380 shares in the last quarter. FMR LLC boosted its position in 10x Genomics by 50.2% during the 2nd quarter. FMR LLC now owns 6,195,527 shares of the company's stock valued at $280,347,000 after buying an additional 2,070,318 shares during the period. BlackRock Inc. raised its holdings in 10x Genomics by 14.2% in the 1st quarter. BlackRock Inc. now owns 9,156,992 shares of the company's stock worth $696,572,000 after purchasing an additional 1,138,358 shares in the last quarter. Baillie Gifford & Co. raised its holdings in 10x Genomics by 13.9% in the 2nd quarter. Baillie Gifford & Co. now owns 8,378,971 shares of the company's stock worth $379,148,000 after purchasing an additional 1,023,207 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in 10x Genomics by 75.5% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,349,229 shares of the company's stock worth $66,907,000 after purchasing an additional 1,010,643 shares in the last quarter. Hedge funds and other institutional investors own 74.34% of the company's stock.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Stories

• Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide
• Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
• Bright Green Corporation Future May be Getting Brighter
• Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.